MALIGNANT SOFT TISSUE NEOPLASM

This adverse event was reported 12 times

These drugs are most commonly taken by patients reporting MALIGNANT SOFT TISSUE NEOPLASM:

# Drug Count
0 DACTINOMYCIN 3
1 MELPHALAN HYDROCHLORIDE 3
2 INTERFERON BETA-1A 2
3 SUNITINIB MALATE 2
4 ANASTROZOLE 1
5 ATENOLOL 1
6 CALCIUM CARBONATE 1
7 CAPECITABINE 1
8 CYCLOPHOSPHAMIDE 1
9 CYCLOPHOSPHAMIDE FOR INJECTION 1
See all common drugs associated with MALIGNANT SOFT TISSUE NEOPLASM

MALIGNANT SOFT TISSUE NEOPLASM is most prevalent among patients taking these drugs:

# Drug Count Frequency
0 DACTINOMYCIN 3 0.0014
1 MELPHALAN HYDROCHLORIDE 3 0.0001
2 FENTANYL CITRATE 1 0.0001
3 SUNITINIB MALATE 2 0.0001
4 EXEMESTANE 1 0.0000
5 IBUPROFEN AND DIPHENHYDRAMINE CITRATE 1 0.0000
6 IMATINIB MESYLATE 1 0.0000
7 VINCRISTINE SULFATE 1 0.0000
8 FULVESTRANT 1 0.0000
9 ANASTROZOLE 1 0.0000
See all drugs enriched for association with MALIGNANT SOFT TISSUE NEOPLASM

MALIGNANT SOFT TISSUE NEOPLASM is most prevalent among patients taking these drug classes:

# Drug class Count Frequency
0 Actinomycin [EPC] 3 0.0014
1 Estrogen Receptor Antagonist [EPC] 1 0.0000
2 Erythropoiesis-stimulating Agent [EPC] 1 0.0000
3 Interferon beta [EPC] 2 0.0000
4 Aromatase Inhibitor [EPC] 1 0.0000
5 Azole Antifungal [EPC] 1 0.0000
6 Alkylating Drug [EPC] 1 0.0000
7 Nucleoside Metabolic Inhibitor [EPC] 1 0.0000
8 beta-Adrenergic Blocker [EPC] 1 0.0000
9 Folate Analog Metabolic Inhibitor [EPC] 1 0.0000
See all drug classes enriched for association with MALIGNANT SOFT TISSUE NEOPLASM